Tolerability of pravastatin in pediatric hematopoietic stem cell transplant patients with bronchiolitis obliterans

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 3, 2010, Pages 185-188

  Duncan, Christine N ^a   Barry, Elly V ^a   Lehmann, Leslie E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bronchiolitis obliterans; Hematopoietic stem cell transplant; Pediatric; Pravachol

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CREATINE KINASE; HEMOGLOBIN; PRAVASTATIN;

ADOLESCENT; ARTICLE; BRONCHIOLITIS OBLITERANS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOCYTE COUNT; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RHABDOMYOLYSIS; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTE COUNT;

ADOLESCENT; ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; BRONCHIOLITIS OBLITERANS; CHILD; CREATINE KINASE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PILOT PROJECTS; PRAVASTATIN; TREATMENT OUTCOME;

EID: 77951050936     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181d32184     Document Type: Article

References (43)

1. Kurland G, Michelson P. Bronchiolitis obliterans in children. Pediatr Pulmonol. 2005;39:193-208.
2. Chan CK, Hyland RH, Hutcheon MA, et al. Small-airways disease in recipients of allogeneic bone marrow transplants. An analysis of 11 cases and a review of the literature. Medicine (Baltimore). 1987;66:327-340.
3. Dudek AZ, Mahaseth H, DeFor TE, et al. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9:657-666.
4. Clark JG, Crawford SW, Madtes DK, et al. Obstructive lung disease after allogeneic marrow transplantation Clinical presentation and course. Ann Intern Med. 1989;111:368-376.
5. Griese M, Rampf U, Hofmann D, et al. Pulmonary complications after bone marrow transplantation in children: twentyfour years of experience in a single pediatric center. Pediatr Pulmonol. 2000;30:393-401.
6. Curtis DJ, Smale A, Thien F, et al. Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;16:169-173.
7. Duncan CN, Buonanno MR, Barry EV, et al. Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41: 971-975.
8. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28:425-434.
9. Schultz KR, Green GJ, Wensley D, et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood. 1994;84:3212-3220.
10. Holland HK, Wingard JR, Beschorner WE, et al. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood. 1988;72:621-627.
11. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168:208-214.
12. Khalid M, Al Saghir A, Saleemi S, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005;25:490-493.
13. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipidlowering drugs. JAMA. 2004;292:2585-2590.
14. Yamamoto S, Kato R. Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. J Dermatol Sci. 1994; 7(suppl):S47-S54.
15. Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy. 1991;11:119S-125S.
16. Stone NJ, Bilek S, Rosenbaum S. Recent national cholesterol education program adult treatment panel III update: adjustments and options. Am J Cardiol. 2005;96:53E-59E.
17. Jones T. The effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Expert Opin Emerg Drugs. 2001; 6:95-109.
18. Diomede L, Albani D, Sottocorno M, et al. In vivo antiinflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 2001;21: 1327-1332.
19. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med. 2000;48: 183-189.
20. Katznelson S, Wang XM, Chia D, et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant. 1998;17:335-340.
21. Wang E, Casciano CN, Clement RP, et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001;18:800-806.
22. Sakai M, Kobori S, Matsumura T, et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis. 1997;133:51-59.
23. Gaugler MH, Vereycken-Holler V, Squiban C, et al. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res. 2005;163:479-487.
24. Weber C, Erl W, Weber KS, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212-1217.
25. Stojanovic I, Vrtovec B, Radovancevic B, et al. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up. J Heart Lung Transplant. 2005;24:1235-1238.
26. Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc. 2004;36: 1539-1541.
27. Kobashigawa JA,Moriguchi JD, Laks H, et al. Ten-year followup of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant. 2005;24:1736-1740.
28. Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med. 2003;167:1271-1278.
29. Philit F, Wiesendanger T, Archimbaud E, et al. Post-transplant obstructive lung disease ("bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J. 1995;8:551-558.
30. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97:61C-68C.
31. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539-540.
32. Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Lopez- Lirola A, et al. Acute rhabdomyolysis associated with cerivastatin therapy. Arch Intern Med. 2001;161:893.
33. Simpson S. Case reports of rhabdomyolysis associated with cerivastatin therapy. Arch Intern Med. 2001;161:2630-2631.
34. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation. 2002;105:2341-2346.
35. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343-370.
36. Hedman M, Neuvonen PJ, Neuvonen M, et al. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther. 2004;75:101-109.
37. Hedman M, Matikainen T, Fohr A, et al. Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. J Clin Endocrinol Metab. 2005;90:1942-1952.
38. Insert PP. Princeton, NJ: Bristol-Myers Squibb Company. 2004.
39. Galanis E, Litzow MR, Tefferi A, et al. Spontaneous pneumomediastinum in a patient with bronchiolitis obliterans after bone marrow transplantation. Bone Marrow Transplant. 1997;20:695-696.
40. Toren A, Or R, Breuer R, et al. Bronchiolitis obliterans presenting as subcutaneous emphysema and pneumomediastinum: a case report. Med Oncol. 1996;13:195-197.
41. Hamadani M, Awan FT, Devine SM. The impact of HMGCoA reductase inhibition on the incidence and severity of graft-Versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood. 2008;111: 3901-3902.
42. Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110:4588-4598.
43. Shimabukuro-Vornhagen A, Liebig T, Von Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood. 2008;112:1544-1545.